175 related articles for article (PubMed ID: 21622644)
1. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Castillo-Tokumori F; Talati C; Al Ali N; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e956-e960. PubMed ID: 32778513
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Daver N; Cortes J; Newberry K; Jabbour E; Zhou L; Wang X; Pierce S; Kadia T; Sasaki K; Borthakur G; Ravandi F; Pemmaraju N; Kantarjian H; Verstovsek S
Haematologica; 2015 Aug; 100(8):1058-63. PubMed ID: 26088933
[TBL] [Abstract][Full Text] [Related]
8. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
9. Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Burgstaller S; Fridrik M; Hojas S; Kühr T; Ludwig H; Mayrbäurl B; Pöhnl R; Pötscher M; Schlögl E; Zauner D; Thaler J; Gisslinger H
Wien Klin Wochenschr; 2013 Apr; 125(7-8):196-9. PubMed ID: 23536018
[TBL] [Abstract][Full Text] [Related]
10. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
12. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
14. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
15. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Livun A; Newberry KJ; Manshouri T; Kusec R; Verstovsek S
Anticancer Res; 2015 Oct; 35(10):5219-23. PubMed ID: 26408680
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
[TBL] [Abstract][Full Text] [Related]
17. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
18. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
[TBL] [Abstract][Full Text] [Related]
19. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Fan WJ; Wu T; Chen JW; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
[TBL] [Abstract][Full Text] [Related]
20. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Schroeder G; Tefferi A
Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]